| Symbol | JSPR |
|---|---|
| Name | JASPER THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, California, 94065, United States |
| Telephone | +1 650 - 549-1400 |
| Fax | — |
| — | |
| Website | https://www.jaspertherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001788028 |
| Description | Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. Additional info from NASDAQ: |
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form SCHEDULE 13G/A - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000895421-26-000171 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001213900-26-053990 <b>Size:</b> 29 KB
Read moreNew Form SCHEDULE 13G/A - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0000886982-26-000153 <b>Size:</b> 18 KB
Read moreNew Form 10-K/A - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001213900-26-050178 <b>Size:</b> 783 KB
Read more(30% Negative) JASPER THERAPEUTICS, INC. (JSPRW) Reports Q1 2026 Financial Results
Read moreJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Read moreJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Read moreNew Form SCHEDULE 13G - Jasper Therapeutics, Inc. <b>Filed:</b> 2026-02-25 <b>AccNo:</b> 0001104659-26-019751 <b>Size:</b> 18 KB
Read moreJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06592768 | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety… | Phase1 | Allergic Asthma | Terminated | 2024-11-26 | 2025-08-11 | ClinicalTrials.gov |
| NCT06736262 | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinica… | Phase2 | Urticaria Chronic | Active_Not_Recruiting | 2024-11-26 | 2026-09-30 | ClinicalTrials.gov |
| NCT06353971 | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Prelimin… | Phase1 | Chronic Inducible Urticaria | Terminated | 2024-03-18 | 2025-07-31 | ClinicalTrials.gov |
| NCT06053567 | Community-based Smoking Cessation Treatment for Adults With High Stress Sensiti… | Phase3 | Nicotine Dependence | Recruiting | 2023-12-27 | 2029-06-30 | ClinicalTrials.gov |
| NCT06162728 | Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminar… | Phase1 | Chronic Spontaneous Urticaria | Active_Not_Recruiting | 2023-11-29 | 2026-10-31 | ClinicalTrials.gov |
| NCT05903274 | JSP191 (briquilimab) in Subjects with LR-MDS | Phase1 | Lower-risk Myelodysplastic Syndrome | Terminated | 2023-06-19 | 2024-10-21 | ClinicalTrials.gov |
| NCT06146738 | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients … | — | Glioblastoma | Recruiting | 2023-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06146725 | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRA… | — | Glioblastoma | Recruiting | 2023-01-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Gr… | — | Glioblastoma | Recruiting | 2022-01-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT04429191 | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic H… | Phase1 | MYELODYSPLASTIC SYNDROME; MDS | Unknown | 2020-07-08 | 2023-12-08 | ClinicalTrials.gov |
| NCT03554785 | Comparative Effectiveness Research to Improve the Health of Sexual and Gender M… | Na | LGBT Health | Completed | 2018-03-01 | 2023-05-31 | ClinicalTrials.gov |
| NCT02963064 | JSP191 Antibody Targeting Conditioning in SCID Patients | Phase1 | SCID | Terminated | 2017-03-20 | 2025-07-07 | ClinicalTrials.gov |
| NCT00251030 | A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfina… | Phase4 | Healthy Volunteers | Completed | 2005-11-01 | 2006-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nicotine patch | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Counseling | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Aerobic Exercise | Other | Phase PHASE3 | Nicotine Dependence | RECRUITING | NCT06053567 |
| Nelfinavir and Omeprazole | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Nelfinavir and Omeprazole | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Nelfinavir and Omeprazole | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Other | Phase PHASE1 | MYELODYSPLASTIC SYNDROME; MDS | UNKNOWN | NCT04429191 |
| Clinician and Non-clinician staff training | Other | Approved | LGBT Health | COMPLETED | NCT03554785 |
| Clinician and Non-clinician staff training | Other | Approved | LGBT Health | COMPLETED | NCT03554785 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Palliative Care | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Palliative Care | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Palliative Care | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146738 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Tumor biopsy | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Tumor resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06146725 |
| Maximal safe resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| Supramaximal resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| Maximal safe resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| Supramaximal resection | Other | Preclinical | Glioblastoma | RECRUITING | NCT06118723 |
| JSP191 | Other | Phase PHASE1 | Lower-risk Myelodysplastic Syndrome | TERMINATED | NCT05903274 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Other | Phase PHASE1 | SCID | TERMINATED | NCT02963064 |
| Placebo Comparator | Other | Phase PHASE1 | Allergic Asthma | TERMINATED | NCT06592768 |
| Briquilimab | Other | Phase PHASE1 | Allergic Asthma | TERMINATED | NCT06592768 |
| Briquilimab | Other | Phase PHASE1 | Chronic Inducible Urticaria | TERMINATED | NCT06353971 |
| Placebo | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06162728 |
| Briquilimab | Other | Phase PHASE1 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06162728 |
| Briquilimab | Other | Phase PHASE2 | Urticaria Chronic | ACTIVE_NOT_RECRUITING | NCT06736262 |
| Nelfinavir and Omeprazole | DRUG | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT00251030 |
| Placebo Comparator | OTHER | Phase PHASE1 | Allergic Asthma | TERMINATED | NCT06592768 |
| Placebo | OTHER | Phase PHASE1 | Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | NCT06162728 |
| Briquilimab | DRUG | Phase PHASE2 | Urticaria Chronic | ACTIVE_NOT_RECRUITING | NCT06736262 |
| JSP191 | DRUG | Phase PHASE1 | Lower-risk Myelodysplastic Syndrome | TERMINATED | NCT05903274 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | BIOLOGICAL | Phase PHASE1 | MYELODYSPLASTIC SYNDROME; MDS | UNKNOWN | NCT04429191 |